321 related articles for article (PubMed ID: 20413364)
1. Cardiovascular computed tomographic assessment of the effect of combination lipoprotein therapy on coronary arterial plaque: rationale and design of the AFRICA (Atorvastatin plus Fenofibric acid in the Reduction of Intermediate Coronary Atherosclerosis) study.
Voros S; Joshi PH; Vazquez G; Roth G; Murrieta L; Rinehart S; Qian Z; Miller J
J Cardiovasc Comput Tomogr; 2010; 4(3):164-72. PubMed ID: 20413364
[TBL] [Abstract][Full Text] [Related]
2. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).
Davidson MH; Rosenson RS; Maki KC; Nicholls SJ; Ballantyne CM; Mazzone T; Carlson DM; Williams LA; Kelly MT; Camp HS; Lele A; Stolzenbach JC
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1298-306. PubMed ID: 24743431
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
[TBL] [Abstract][Full Text] [Related]
4. Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.
Davidson M; Rosenson RS; Maki KC; Nicholls SJ; Ballantyne CM; Setze C; Carlson DM; Stolzenbach J
Cardiovasc Drugs Ther; 2012 Aug; 26(4):349-58. PubMed ID: 22622962
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of a randomized clinical study to investigate the effect of ezetimibe, a cholesterol absorption inhibitor, on the regression of intracoronary plaque evaluated by non-obstructive angioscopy and ultrasound: The ZIPANGU study.
Hiro T; Hirayama A; Ueda Y; Komatsu S; Matsuoka H; Takayama T; Ishihara M; Hayashi T; Saito S; Kodama K;
J Cardiol; 2014 Dec; 64(6):501-7. PubMed ID: 24725763
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Jones PH; Bays HE; Davidson MH; Kelly MT; Buttler SM; Setze CM; Sleep DJ; Stolzenbach JC
Clin Drug Investig; 2008; 28(10):625-34. PubMed ID: 18783301
[TBL] [Abstract][Full Text] [Related]
7. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study.
Choi SH; Chae A; Miller E; Messig M; Ntanios F; DeMaria AN; Nissen SE; Witztum JL; Tsimikas S
J Am Coll Cardiol; 2008 Jul; 52(1):24-32. PubMed ID: 18582631
[TBL] [Abstract][Full Text] [Related]
8. Prevention of atherosclerosis progression using atorvastatin in normolipidemic coronary artery disease patients--a controlled randomized trial.
Shukla A; Sharma MK; Jain A; Goel PK
Indian Heart J; 2005; 57(6):675-80. PubMed ID: 16521637
[TBL] [Abstract][Full Text] [Related]
9. Clinically evident polyvascular disease and regression of coronary atherosclerosis after intensive statin therapy in patients with acute coronary syndrome: serial intravascular ultrasound from the Japanese assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) trial.
Hibi K; Kimura T; Kimura K; Morimoto T; Hiro T; Miyauchi K; Nakagawa Y; Yamagishi M; Ozaki Y; Saito S; Yamaguchi T; Daida H; Matsuzaki M;
Atherosclerosis; 2011 Dec; 219(2):743-9. PubMed ID: 21899843
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
[TBL] [Abstract][Full Text] [Related]
11. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
12. Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: a randomized prospective study.
Yokoyama M; Komiyama N; Courtney BK; Nakayama T; Namikawa S; Kuriyama N; Koizumi T; Nameki M; Fitzgerald PJ; Komuro I
Am Heart J; 2005 Aug; 150(2):287. PubMed ID: 16086932
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
[TBL] [Abstract][Full Text] [Related]
14. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial.
Arad Y; Spadaro LA; Roth M; Newstein D; Guerci AD
J Am Coll Cardiol; 2005 Jul; 46(1):166-72. PubMed ID: 15992652
[TBL] [Abstract][Full Text] [Related]
15. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
Costet P; Hoffmann MM; Cariou B; Guyomarc'h Delasalle B; Konrad T; Winkler K
Atherosclerosis; 2010 Sep; 212(1):246-51. PubMed ID: 20619837
[TBL] [Abstract][Full Text] [Related]
16. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results.
Budoff MJ; Muhlestein JB; Bhatt DL; Le Pa VT; May HT; Shaikh K; Shekar C; Kinninger A; Lakshmanan S; Roy SK; Tayek J; Nelson JR
Cardiovasc Res; 2021 Mar; 117(4):1070-1077. PubMed ID: 32609331
[TBL] [Abstract][Full Text] [Related]
17. Impact of atorvastatin treatment in first-degree relatives of patients with premature coronary artery disease with endothelial dysfunction: a double-blind, randomized, placebo-controlled crossover trial.
Hong SJ; Chang HJ; Park S; Kang DR; Shin S; Cho IJ; Shim CY; Hong GR; Ha JW; Chung N
Clin Cardiol; 2013 Aug; 36(8):480-5. PubMed ID: 23754711
[TBL] [Abstract][Full Text] [Related]
18. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
Nissen SE
Am J Cardiol; 2005 Sep; 96(5A):61F-68F. PubMed ID: 16126025
[TBL] [Abstract][Full Text] [Related]
19. Use of ivabradine and atorvastatin in emergent orthopedic lower limb surgery and computed tomography coronary plaque imaging and novel biomarkers of cardiovascular stress and lipid metabolism for the study and prevention of perioperative myocardial infarction: study protocol for a randomized controlled trial.
Rudd N; Subiakto I; Asrar Ul Haq M; Mutha V; Van Gaal WJ
Trials; 2014 Sep; 15():352. PubMed ID: 25195125
[TBL] [Abstract][Full Text] [Related]
20. Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial.
Houslay ES; Cowell SJ; Prescott RJ; Reid J; Burton J; Northridge DB; Boon NA; Newby DE;
Heart; 2006 Sep; 92(9):1207-12. PubMed ID: 16449511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
